RHEI is derived from Heraclitus’ quote “Panta rhei” (πάντα ῥεῖ – “everything flows”), which means that the whole reality is an ever-flowing stream, and that nothing is ever still, not even for a moment. Similarly, our business philosophy is based on the constant need to adapt and evolve in line with ever-changing pharmaceutical eco-system, just like the world around us, constantly changing and becoming more complex.
Every single day of our operations we are striving to be more innovative, original and flexible. Most importantly, LIFE is our constant reminder that each of our endeavours must be aimed at improving the quality of life and that successful business is not a goal in itself, but rather that we are here primarily because of the people who need our help.
Who we are
Rhei Life is a privately held pharmaceutical company established in 2015 with the vision of creating an innovative and efficient pharmaceutical value chain, thus improving the accessibility and availability of pharmaceutical products to millions of people.
Rhei Life is a collaboration partner and solution provider of unique and high-quality products to many healthcare companies across the world. Through innovative models of cooperation, we are reaching millions of patients. The company has been operating since 2015 through three divisions: Consumer Healthcare (CHC), Hospital Medicines and Unregistered Medicines. Our product portfolio of Medicines, Food Supplements and Medical Devices covers a broad range of therapeutic indications, including Women’s Healthcare, Pain & Inflammation, Pediatrics, Neurology, Oncology, Gastroenterology, Urology, Hematology and Dermatology.
We are a partner-centric company, striving to be the global provider of choice by introducing new standards and innovative business models in pharma industry.
By now we have signed partnerships with 80+ companies from 35+ countries worldwide (North America, South America, Europe, Asia and India).
We have 90+ granted Marketing Authorizations from National Health Authorities across different markets, with 51 SKUs in process of registration and dozens of others in the pipeline, pending to be submitted. These accomplishments, among many others, give us confidence that we shall achieve the objective of becoming a well-recognized global partner and the top regional player in pharmaceutical industry by 2026.